Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws NDA
October 07, 2014 at 08:32 AM EDT
Given the rapidly evolving hepatitis C (HCV) treatment landscape in the U.S., Bristol-Myers Squibb (NYSE: BMY) has decided that it will ...